RT Journal Article
SR Electronic
T1 UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.24.24315748
DO 10.1101/2024.10.24.24315748
A1 Brandt, Anna
A1 Klinghammer, Konrad
A1 Schultheiss, Christoph
A1 Paschold, Lisa
A1 Wickenhauser, Claudia
A1 Bauer, Marcus
A1 Bergqvist, Anna
A1 Hahn, Dennis
A1 Schafhausen, Philippe
A1 Tometten, Mareike
A1 Blaurock, Markus
A1 Zech, Henrike Barbara
A1 Busch, Chia-Jung
A1 Dietz, Andreas
A1 Müller-Richter, Urs
A1 Alt, Jürgen
A1 Boehm, Andreas
A1 Kowoll, Simone
A1 Steighardt, Jörg
A1 Lasch, Alexander
A1 Hagen Westgaard, Ingunn
A1 Westhrin, Marita
A1 Stein, Alexander
A1 Hinke, Axel
A1 Binder, Mascha
YR 2024
UL http://medrxiv.org/content/early/2024/10/24/2024.10.24.24315748.abstract
AB Background Human telomerase reverse transcriptase (hTERT) is highly expressed (75-100%) in head and neck squamous cell carcinoma (HNSCC). The FOCUS study examines the role of the hTERT-directed vaccine UV1 in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.Methods The FOCUS trial, a two-armed, open-label, non-comparative, randomized, multicenter phase 2 study, was designed to assess the efficacy and feasibility of UV1 as an add-on to pembrolizumab in the first-line treatment of patients with R/M PD-L1 positive HNSCC. A progression-free survival rate at 6 months (PFSR@6) of 40% was deemed promising for further development in a phase 3 setting. The trial was conducted in 10 centers in Germany.Results From August 2021 to July 2023, 25 patients were enrolled in the calibration arm A and 50 patients in the UV1 arm B. Median age was 65 years and 18% of patients had an ECOG performance score of 2. The PFSR@6 was 30% in the UV1 arm. No specific safety signals were observed in the UV1 arm apart from a reversible allergic reaction that appeared in one patient. At a median follow-up of almost one year (11.3 months), median overall survival was 13.1 months in the calibration arm A and 12.6 months in the UV1 arm B. Clinical trial identification number NCT05075122.Conclusions The addition of UV1 to pembrolizumab was safe but did not show an efficacy signal in this study population.Competing Interest StatementMascha Binder received institutional research grants from Merck, BMS, Hexal, Novartis, German Cancer Aid (Krebshilfe), German Research Foundation and the Federal Ministry of Education and Research as well as honoraria for lectures and advisory board meetings by Celgene, Janssen, Gilead, Merck, Roche, Amgen, Sanofi-Aventis and BMS. She received funding for the FOCUS trial from ULTIMOVACS. Alexander Stein received research funding from MSD and serves as an advisory board member for MSD. Urs Mueller-Richter serves as a consultant or advisor and/or received honoraria from AstraZeneca, BioNTech, BMS, KuraOncology, Merck, MSD, Novartis, and Sanofi. Juergen Alt serves as an advisor for AstraZeneca, MSD, Novartis, Roche, BMS, Janssen, and Merck and received honoraria from AstraZeneca, BMS, Roche, and Boehringer Ingelheim. Konrad Klinghammer serves as a consultant or advisor and/or received honoraria from MSD, Merck, BMS, Roche, Novartis, Sanofi, Bayer, BioNTech, Boehringer Ingelheim, and onkowissen. Anna Brandt received honoraria from Merck. Dennis Hahn serves as a consultant or advisor and/or received honoraria from BMS, MSD and Merck. Henrike Barbara Zech serves as a consultant and /or received honoraria from MSD, Merck, BMS, Sanofi, Regeneron. Chia-Jung Busch received institutional research grants from BMS and German Cancer Aid (Krebshilfe) as well as honoraria for lectures and advisory board meetings by Bayer, BMS, GSK, Merck, MSD, Sanofi-Aventis. Ingunn Hagen Westgaard, Anna Bergqvist and Marita Westhrin are employed by Ultimovacs ASA. Philippe Schafhausen serves as a consultant or advisor and/or received honoraria from Alexion, AOP Orphan Pharmaceutical, Blueprint Medicines, GSK, MSD, Merck, BMS, Novartis, Pfizer, Roche, Sanofi, and Sobi. All other authors declare no potential conflict of interest.Clinical TrialClinical trial identification number NCT05075122Funding StatementThe trial including translational research was funded by a research grant from ULTIMOVACS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was conducted at 10 centers in Germany in compliance with the Declaration of Helsinki. All participants provided written informed consent. Ethical approval was given by all of the following Ethics committees: Ethics Committee of the Medical Faculty of Martin Luther University Halle-Wittenberg, Halle Saale, Germany Ethics Committee at the Medical Faculty of Leipzig University, Leipzig, Germany Ethics Committee of the State Medical Association, Mainz, Germany Ethics Committee at the Medical Faculty of RWTH Aachen, Aachen, Germany Ethics Committee at the State Medical Association of Baden-Wuerttemberg, Stuttgart, Germany Ethics Committee of the State of Berlin, Berlin, Germany Ethics Committee of the Medical Association Hamburg, Hamburg, Germany Ethics Committee of the Medical Faculty of the University of Wuerzburg, Wuerzburg, Germany Ethics Committee at the University Medical Center Greifswald, Institute of Pharmacology, Greifswald, Germany Ethics Committee of the Saxon State Medical Association, Dresden, Germany I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.